Appointments at Aphena, Acino and blue inspection body – People on the move

By Nick Taylor

- Last updated on GMT

Related tags: Blue inspection body, Medicine

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Aphena, Acino and blue inspection body.

Thomas Bieringer ​has been appointed as managing director of INVITE GmbH​, a manufacturing research joint venture between Bayer Technology Services and Technical University Dortmund. Bieringer has worked at Bayer since 1997.

Aphena Pharma Solutions​ has named Mary Foster​ as vice president (VP) of quality and regulatory affairs. Foster has worked in the sector for 25 years, most recently at Catalent Pharma Solutions.

Kip Martin​ has joined Columbia Laboratories​ (as VP, business development. Martin has served as a consultant to Columbia Laboratories in recent months while also supporting Inspirion Delivery Techonologies.

Blue inspection body Gmbh ​has hired Bohong Meng​ as co-auditor. Meng will be focused on assessing good manufacturing practices (GMP) of Asian active pharmaceutical ingredient (API) producers.

Christian Pangratz​ has been appointed as chief business officer at Activaero​. Pangratz joins from Nektar Therapeutics to succeed Henrik Luessen ​who has left to focus on his consultancy business. Luessen will continue to support Activaero on a part time basis.

Acino​ has added Ulf-Hergen Westphal​ to group management. Westphal joined Acino as head group quality on March 1 2011 after holding similar positions at several pharmaceutical companies.

Jeffrey Walsh ​has joined bluebird bio ​as chief operating officer. Walsh has previously worked at Taligen Therapeutics, Inotek Pharmaceuticals, EXACT Sciences, PathoGenesis and SmithKline Beecham. Bluebird bio has also added Daniel Lynch​ to its board of directors.

Xanodyne Pharmaceuticals​ has named Fabrice Egros​ as chief operating officer. Egros has 20 years of pharmaceutical experience from working at UCB, Sanofi and Parke-Davis.

Allen Barnett​ has stepped down as CEO of Kinex Pharmaceuticals​. Barnett was the founding CEO of Kinex and will be succeeded by Johnson Lau​, who is currently executive chairman of the company. Lau has worked at Ribapharm, ICN Pharmaceuticals and Schering-Plough.

Related topics: Markets & Regulations

Related news

Show more

Follow us

Products

View more

Webinars